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Abstract
Background: Cross-sectional and retrospective studies have associated major depressive disorder with glial activation and
injury as well as blood–brain barrier disruption, but these associations have not been assessed prospectively. Here, we
aimed to determine the relationship between changes in depressive symptom severity and in blood levels of S-100 calcium-
binding protein B (S-100B), high-sensitivity C-reactive protein, and interleukin-6 following an inflammatory challenge.
Methods: Fifty unselected participants were recruited from a randomized, controlled trial comparing coronary artery bypass
grafting procedures performed with versus without cardiopulmonary bypass for the risk of neurocognitive decline.
Depressive symptom severity was measured at baseline, discharge, and six-month follow-up using the Beck Depression
Inventory II (BDI-II). The primary outcome of the present biomarker study was acute change in depressive symptom severity,
defined as the intra-subject difference between baseline and discharge BDI-II scores. Blood biomarker levels were
determined at baseline and 2 days postoperative.
Results: Changes in S-100B levels correlated positively with acute changes in depressive symptom severity (Spearman r,
0.62; P = 0.0004) and accounted for about one-fourth of their observed variance (R2, 0.23; P = 0.0105). This association
remained statistically significant after adjusting for baseline S-100B levels, age, weight, body-mass index, or b-blocker use,
but not baseline BDI-II scores (P = 0.064). There was no statistically significant association between the primary outcome and
baseline S-100B levels, baseline high-sensitivity C-reactive protein or interleukin-6 levels, or changes in high-sensitivity C-
reactive protein or interleukin-6 levels. Among most participants, levels of all three biomarkers were normal at baseline and
markedly elevated at 2 days postoperative.
Conclusions: Acute changes in depressive symptom severity were specifically associated with incremental changes in S-
100B blood levels, largely independent of covariates associated with either. These findings support the hypothesis that glial
activation and injury and blood–brain barrier disruption can be mechanistically linked to acute exacerbation of depressive
symptoms in some individuals.
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Introduction
A large body of evidence substantiates the association between
inflammation and major depressive disorder [1–13]. Cross-
sectional and retrospective studies of depression have documented
microglial activation and proliferation [3,4,14] as well as astroglial
loss in biopsied and post-mortem brain tissue [15–18], and
increased Th1 proinflammatory cytokines in cerebrospinal fluid
(CSF) and blood samples [6–12] (recently reviewed in [1]). In
addition, population-level studies identify autoimmune diseases
and severe infections as risk factors for depression [19,20].
Prospective etiologic [5,21–31] and treatment studies [3,32–35]
have provided some of the most direct evidence supporting the
hypothesis that inflammation can be causally related to depressive
symptoms. The prototypical etiologic studies in this regard are the
so-called inflammation-challenge paradigms, such as interferon-a
administration [36]. Among those treated with interferon-a,
typically for hepatitis C or cancer, about half experience acute-
onset depression in association with systemic inflammatory and
neuroimaging abnormalities [5,21–31]. These inflammation-chal-
lenge paradigms have also been extended to include orthopedic
surgery [37], and more recently–cardiac surgery [38,39], in which
the occurrence of a robust systemic inflammatory response is well-
established [40].
A related and emerging area of research in psychoimmunology
has focused on elucidating the connections among inflammatory
abnormalities as well as glial activation and injury and blood–
brain barrier disruption in depression [2,3]. Like inflammation,
evidence of glial activation and injury in depression has been
extensively documented [1]. Despite this, however, and notwith-
standing the necessary functions of astroglial–endothelial interac-
tions in maintaining blood–brain barrier integrity [35], only
recently has evidence linking blood–brain barrier disruption to
depression begun to accumulate [2,3]. Evidence to this effect
includes histological and ultrastructural findings in biopsied and
post-mortem brain tissue [3,41]; elevated CSF-to-serum albumin
ratios [42–44]; reduced flow-mediated dilation (a surrogate of
endothelial dysfunction) [45]; increased vascular disease comor-
bidity [46,47]; and elevated blood levels of endothelial dysfunction
biomarkers (e.g., intercellular adhesion molecule 1, vascular
adhesion molecule 1, E-selectin, and P-selectin) [48–61].
S-100 calcium-binding protein B (S-100B) is a 10 kDa protein,
consisting of 92 amino acids and two EF-hand domains, that is
implicated in the pathophysiology of major depressive disorder
[55,59,62–71] and various neurological disorders [72–74]. S-100B
is produced and secreted by both intracerebral (i.e., mainly
astrocytes, and to a lesser degree, oligodendrocytes) and extra-
cerebral sources (e.g., adipocytes and myocytes) [72], and is
involved in numerous regulatory and immune pathways [75,76].
Elevated blood S-100B levels are considered a marker of glial
activation and injury [72,74,77–87] as well as blood–brain barrier
disruption [72,81,88–93], and have been associated with suicid-
ality [56], lower Glasgow Coma Scale scores [73], greater
post-concussive symptom severity [74], ictal events [72], and
greater risk of postoperative cognitive decline [94–97] (in addition
to numerous other clinically significant outcomes). To date,
however, no studies have simultaneously assessed the relationships
between depression and glial activation and injury, blood–brain
barrier disruption, and inflammation using a prospective design.
Here, we aimed to address this gap in the literature by evaluating
perioperative changes in blood levels of S-100B, high-sensitivity C-
reactive protein (hs-CRP), and interleukin-6 for changes in
depressive symptom severity in the inflammation-challenge
paradigm of cardiac surgery.
Materials and Methods
Design, setting, and participants
This is a prospective cohort study nested within a randomized,
controlled trial. An unselected group of 50 participants was
recruited from among 201 patients undergoing coronary artery
bypass grafting in the context of a randomized, controlled trial
comparing conventional vs off-pump procedures for the risk of
neurocognitive decline (Scarecrow trial, 2001–2004) [98]. Inclu-
sion criteria were ages 40 to 80 years, clinical indication for urgent
or elective coronary artery bypass grafting, referral to the
Cardiothoracic Surgery service at Eastern Maine Medical Center
(Bangor, Maine, United States), and capacity to provide written
informed consent. Exclusion criteria were concomitant surgical
procedures, severe calcification of the ascending aorta or deep
intra-myocardial left anterior descending coronary artery, recent
administration of an inotropic agent in excess of 3 mg/kg/min,
requiring a cardiac-assist device for hemodynamic instability, and
not providing written informed consent. Details of the surgical and
anesthesia protocols used in the trial have been described
previously [98]. All participants provided written informed
consent. The Institutional Review Board of Eastern Maine
Medical Center approved this study.
Biochemical measurements
Blood samples were collected by standard venipuncture at
baseline and approximately 2 days postoperative. Upon collection,
samples were stored at 280uC and then transferred on dry ice to
the Laboratory for Clinical and Biochemical Research (Colchester,
Vermont, United States) where S-100B, hs-CRP, and interleukin-
6 blood levels were determined in either plasma or serum.
Enzyme-linked immunosorbent assays were used to determine S-
100B (#364701D, DiaSorin, Bromma, Sweden) and interleukin-6
blood levels (#HS600B, R&D Systems, Minnesota, United States).
An automated BNII nephelometer was used to perform an
S-100B, hS-CRP, and IL-6 for Changes in Depressive Symptom Severity
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immunonephelometric assay to determine hs-CRP blood levels
(Siemens Healthcare Diagnostics, Illinois, United States). All
laboratory personnel were blinded to participant characteristics
and clinical information.
Lower limits of detection were 0.02 mg/l for S-100B, 0.16 mg/l
for hs-CRP, and 0.16 pg/ml for interleukin-6. Inter-assay
coefficients of variance at baseline and 2 days postoperative were
6.01% and 3.31% for S-100B, 2.93% and 1.82% for hs-CRP, and
7.95% and 8.71% for interleukin-6. In determining S-100B and
interleukin-6 blood levels, each sample was run twice, the
arithmetic mean of which was taken as the final value. In
determining hs-CRP blood levels, each sample was run once, as
the assays were automated. The approximate upper limits of
normal blood levels for each biomarker are 0.15 mg/l for S-100B,
10.0 mg/l for hs-CRP, and 5.0 pg/ml for interleukin-6. hs-CRP
levels less than or equal to 1.0 mg/l are indicative of low risk for
ischemic heart disease, 1.0 to 3.0 mg/l moderate risk, and 3.0 to
10.0 mg/l high risk. hs-CRP levels greater than or equal to
10.0 mg/l are indicative of acute systemic inflammation of a non-
cardiac origin (e.g., as occurs with infection or cardiac surgery).
The change (i.e., intra-subject difference) between blood levels of
each biomarker at baseline and 2 days postoperative was
computed for each participant. Instances where 2-day postoper-
ative blood levels were greater than baseline levels (for a given
biomarker and participant), were considered a positive change
(i.e., perioperative increases). Likewise, when 2-day postoperative
blood levels were less than baseline levels, this was considered a
negative change (i.e., perioperative decreases).
Main outcomes
Depressive symptom severity was assessed at baseline, discharge,
and six-month month follow-up using the Beck Depression
Inventory II (BDI-II). Scores ranging from 0 to 13 indicate
subclinical or minimal depressive symptom severity, 14 to 19 mild,
20 to 28 moderate, and 29 to 63 severe [99]. Participants, family
members, treating clinicians, BDI-II test examiners, and all other
trial staff in contact with participants were blinded to the results of
blood biomarker levels. The primary outcome of the present
biomarker study, acute change in depressive symptom severity,
was defined as the intra-subject difference between baseline and
discharge BDI-II scores. The secondary outcome, delayed change
in depressive symptom severity, was defined as the intra-subject
difference between baseline and six-month follow-up BDI-II
scores.
Statistical analysis
Analyses were done using Stata version 12.1 for Mac
(StataCorp, LP. College Station, Texas, United States). Participant
characteristics were summarized as the arithmetic mean 6
standard deviation for continuous data and frequency and
percentage for categorical data. These descriptive statistics were
then compared between the biomarker and non-biomarker
cohorts that comprised the Scarecrow trial with the use of two-
Figure 1. Paired distributions of Beck Depression Inventory II
scores and blood biomarker measures. (A) Beck Depression
Inventory II scores at baseline, discharge, six-month follow-up; (B) S-
100 calcium-binding protein B levels at baseline, 2 days postoperative,
and the total change between them; (C) high-sensitivity C-reactive
protein levels at baseline 2 days postoperative, and the total change
between them; (D) inteleukin-6 levels at baseline 2 days postoperative,
and the total change between them. Values given below the x-axis are
arithmetic mean 6 standard deviation. BDI-II = Beck Depression
Inventory II. hs-CRP= high-sensitivity C-reactive protein. IL-6 = interleu-
kin-6. S-100B= S-100 calcium-binding protein B.
doi:10.1371/journal.pone.0111110.g001
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tailed Student t tests for continuous data and Cochran–Mantel–
Haenszel x2 tests for categorical data. To identify covariates of
blood biomarker measures at baseline and their differences
between baseline and postoperative assessments and/or the main
outcomes, Spearman rank correlation coefficients (Spearman r)
were calculated for all possible two-term combinations, applying
the pairwise deletion method for comparisons involving missing
data. Participant characteristics that yielded statistically significant
Table 1. Prospective biomarker cohort, nested within the Scarecrow trial (2001–2004).
Biomarker cohort Non-biomarker cohort P Value*
(n=50) (n=151)
Age (years) 63.068.3 64.269.5 0.43
Female 6 (12.0) 34 (22.5) 0.11
Weight (kg) 87.7612.9 88.3614.9 0.83
Height (cm) 172.569.3 172.868.8 0.87
Body-mass index (kg/m2) 29.563.8 29.564.2 0.95
History of vascular disease 8 (16.0) 34 (22.5) 0.33
History of diabetes mellitus 17 (34.0) 49 (32.5) 0.84
History of COPD 3 (6.0) 13 (8.6) 0.56
History of smoking 10 (20.0) 28 (18.5) 0.82
Charlson comorbidity index 0.6260.70 0.7760.92 0.28
Myocardial infarction{ 8 (16.0) 17 (11.3) 0.38
Unstable angina at admission 35 (70.0) 88 (58.3) 0.14
Two-vessel disease 18 (36.0) 43 (28.5) 0.32
Three-vessel disease 27 (54.0) 85 (56.3) 0.78
Left-ventricular ejection fraction (%)` 61.4610.8 58.9613.3 0.25
Troponin T at 24 hours (ng/dl) 0.6260.61 0.5861.01 0.77
NYHA class (I-IV)1 1.7060.83 1.7560.85 0.75
Serum creatinine (mg/dl) 1.0560.24 1.1560.73 0.33
b-blocker 39 (78.0) 112 (74.2) 0.59
ACE-inhibitor 11 (22.0) 49 (32.5) 0.16
Ca2+ channel blocker 11 (22.0) 24 (15.9) 0.32
Acetylsalicylic acid{ 39 (78.0) 106 (70.2) 0.29
Randomized to off-pump procedure 23 (46.0) 76 (50.3) 0.60
Underwent off-pump procedure 21 (42.0) 70 (46.4) 0.59
Urgent priority procedure 30 (60.0) 95 (62.9) 0.71
Time from baseline to procedure (days) 3.163.6 2.663.3 0.34
Time from procedure to discharge (days) 6.062.6 7.364.9 0.08
BDI-II (score), baseline (n = 42; n = 145) 8.265.6 9.666.9 0.23
BDI-II (score), discharge (n = 40; n = 121) 7.264.3 9.866.7 0.026
BDI-II (score), 6 months (n = 26; n = 105) 6.965.5 7.867.4 0.59
BDI-II (score), acute D (n = 39; n = 120)|| 20.764.6 0.065.4 0.43
BDI-II (score), delayed D (n = 25; n = 104)" 20.564.8 21.865.7 0.29
Values are arithmetic mean 6 standard deviation for continuous data, and frequency (percentage) for categorical data. The Scarecrow trial compared CABG performed
with vs. without cardiopulmonary bypass for the risk of postoperative neurocognitive decline (defined as a $20% reduction on $20% of 19 psychometrics) among 201
patients at Eastern Maine Medical Center. Abbreviations: ACE = angiotensin-converting enzyme. CABG= coronary artery bypass grafting. COPD= chronic obstructive
pulmonary disease. hs-CRP = high-sensitivity C-reactive protein. NYHA=New York Heart Association. S-100B = S-100 calcium-binding protein B.
*Two-tailed Student t test for continuous data; x2 test for categorical data.
{Within 7 days before the index procedure.
`Missing data for: n = 3; n = 19.
1Missing data for: n = 3; n = 3.
||Acute D refers to the primary outcome, acute change in depressive symptom severity, defined as the intra-subject difference between BDI-II scores at baseline and
discharge.
"Delayed D refers to the secondary outcome, delayed change in depressive symptom severity, defined as the intra-subject difference between BDI-II scores at baseline
and six-month follow-up.
doi:10.1371/journal.pone.0111110.t001
S-100B, hS-CRP, and IL-6 for Changes in Depressive Symptom Severity
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correlations were entered into the relevant multiple linear
regression models (see below).
Spearman r values were calculated and scatterplots generated
for all possible two-term combinations between and among blood
biomarker measures at baseline and postoperative assessments,
and the difference between them and BDI-II scores at baseline,
discharge, six-month follow-up, the difference between baseline
and discharge BDI-II scores (primary outcome), and the difference
between baseline and six-month follow-up BDI-II scores (second-
ary outcome). For statistically significant correlations between
blood biomarker measures and the main outcomes, we did
sensitivity analysis by recalculating Spearman r values using
Bonferroni-adjusted significance levels and again using Sidak-
adjusted significance levels. Last, the main outcomes were
regressed on blood biomarker measures at baseline and the
difference between blood biomarker levels at baseline and
postoperative assessments using ordinary-least squares simple
and multiple linear regressions. Before entering terms into the
models, variable transformations were first applied to all variables
that did not have a normal distribution. The transformation used
for a given variable was based on the lowest x2 value yielded by a
ladder of powers analysis [100].
Results
Biomarker cohort
The pairwise distributions of BDI-II scores and blood biomark-
er levels are displayed in Figure 1. Participant characteristics and
BDI-II scores were generally similar among those comprising the
biomarker cohort relative to the remaining participants in the
Scarecrow trial (Table 1). One exception was discharge BDI-II
scores, which were lower on average among those in the
biomarker cohort (Table 1).
Covariate assessment
Spearman r values for comparisons between participant
characteristics and the main outcomes and blood biomarker
measures are displayed in Table 2. None of the participant
characteristics showed a statistically significant correlation with
either outcome (Table 2). Intra-subject differences between
baseline and postoperative S-100B levels correlated positively
with age and negatively with weight and body-mass index, and
were significantly lower on average among those taking b-blockers
(Table 2). Perioperative increases in hs-CRP levels correlated
negatively with age. Perioperative increases in hs-CRP and
Figure 2. Scatterplot matrix of all possible combinations between and among Beck Depression Inventory II scores and blood
biomarker measures. BDI-II scores were assessed at baseline, discharge, and 6 months. Differences between baseline and discharge BDI-II scores
(primary outcome) and baseline and 6-month BDI-II scores (secondary outcome) were computed for each participant. Biomarker levels were
determined at baseline and 2 days postoperatively, and change scores computed. BDI-II = Beck Depression Inventory II. hs-CRP= high-sensitivity C-
reactive protein. IL-6 = interleukin-6. S-100B= S-100 calcium-binding protein B.
doi:10.1371/journal.pone.0111110.g002
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interleukin-6 levels were significantly greater on average among
participants randomized to (intention-to-treat) and having under-
gone (as-treated) off-pump procedures, as compared with those
randomized to and having undergone conventional procedures
(Table 2). Spearman r values and scatterplots for all possible two-
term combinations between and among BDI-II scores and blood
biomarker measures are displayed in Table 3 and Figure 2.
Acute change in depressive symptom severity
Intra-subject differences between baseline and postoperative
S-100B levels exhibited a strong positive correlation with
intra-subject differences between baseline and discharge BDI-II
scores (Spearman r, 0.62; P= 0.0004; Table 3; Figure 3). Neither
the strength nor the statistical significance of this correlation was
affected by Bonferroni- or Sidak-adjusted significance levels (for
both adjustments: Spearman r, 0.62; P = 0.0004). There were no
other statistically significant correlations between blood biomarker
measures and the primary outcome (Table 3). Significant negative
correlations were observed between baseline BDI-II scores and
changes in S-100B levels and between baseline BDI-II scores and
acute changes in depressive symptom severity (Table 3).
The results of simple and multiple linear regressions of the
primary outcome on blood biomarker measures are displayed in
Table 4. A simple linear regression model showed that each 0.10-
mg/l increase in intra-subject differences between baseline and
postoperative S-100B levels was associated with a 1.36-point
increase in intra-subject differences between baseline and
discharge BDI-II scores (regression coefficient [R] = 13.60, coef-
ficient of determination [R2] = 0.23, t=2.76, P= 0.010, standard-
ized regression coefficient [b] = 0.48, F(1,26) = 7.61, P = 0.0105;
Table 4; Figure 3). This association remained statistically signif-
icant after individual adjustments for baseline S-100B levels, age,
weight, body-mass index, and b-blocker use, but not baseline BDI-
II scores (R=9.18, R2=0.40, t=1.94, P = 0.064) adjusting for
which improved the explanatory power of the model overall
(b=0.32, R2adjusted = 0.35, F(2,25) = 8.29, P model = 0.0017; Ta-
ble 4). There were no statistically significant associations between
the primary outcome and the remaining blood biomarker
measures (Table 3; Table 4).
Delayed change in depressive symptom severity
Spearman r values and scatterplots for all possible two-term
combinations between the secondary outcome and blood bio-
marker measures are displayed in Table 3 and Figure 2. There
were no statistically significant correlations between blood
biomarker levels and the secondary outcome (Table 3). The
results of simple and multiple linear regressions of the secondary
outcome on blood biomarker levels are displayed in Table 5.
None of these models, unadjusted or adjusted, yielded a
statistically significant relationship between blood biomarker levels
and delayed change in depressive symptom severity (Table 5).
Discussion
This is the first study, to our knowledge, to have prospectively
assessed the relationships between blood biomarkers of glial
Figure 3. Association between perioperative increases in blood levels of S-100 calcium-binding protein B and acute changes in
depressive symptom severity. The x-axis refers to the intra-subject difference between S-100 calcium binding protein B (S-100B) levels measured
at baseline and 2 days postoperative. The y-axis refers to the primary outcome, acute change in depressive symptom severity, defined as the intra-
subject difference between baseline and discharge Beck Depression inventory II (BDI-II) scores. BDI-II = Beck Depression Inventory II. S-100B= S-100
calcium-binding protein B. Spearman rho= Spearman rank correlation coefficient.
doi:10.1371/journal.pone.0111110.g003
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activation and injury, blood–brain barrier disruption, and
depressive symptom severity in the context of the systemic
inflammatory challenge paradigm of coronary artery bypass
grafting. We found that perioperative increases in the glial
activation and injury and blood–brain barrier-disruption biomark-
er, S-100B, exhibited a strong positive correlation with acute
changes in depressive symptom severity, largely independent of
covariates associated with either. Given the magnitude of the test
statistic for this correlation (P = 0.0004), the statistical significance
of this finding cannot readily be attributed to the fact that we
did multiple pre-specified comparisons that included assessing
the relationship between depressive symptoms and two other
biomarkers besides S-100B (a/comparisons = [0.05]/[3] = 0.001.
0.0004). We also found that baseline BDI-II scores correlated
negatively with both perioperative increases in S-100B levels as
well as acute changes in depressive symptom severity, and that
adjusting for baseline BDI-II scores diminished the strength and
statistical significance of their association (the term for perioper-
ative increases in S-100B levels still approached statistical
significance at P= 0.064). Adjusting for baseline BDI-II scores
also increased the proportion of variance in the primary outcome
explained by the model (from 23% to 35%). Exploratory analyses
indicated that the association between perioperative increases in S-
100B levels and acute changes in depressive severity remained
statistically significant after adjusting for baseline BDI-II scores
among participants with BDI-II scores greater than or equal to 5
at baseline (Spearman r, 0.66; P = 0.0007). This was not the case,
however, among those with BDI-II scores less than 5 at baseline
(Spearman r, 0.15; P= 0.15).
Two earlier studies assessed relationships between depression
and inflammation in the context of coronary artery bypass grafting
[38,39]. In the first of these, Yang and colleagues found that mean
levels of hs-CRP at baseline were significantly higher among those
with clinical depression at six-month follow-up (defined as a
Patient Health Questionnaire (PHQ-9) score $9) compared with
those who were not [38]. By comparison, the correlation between
baseline blood levels of hs-CRP blood levels and six-month BDI-II
scores in the present study was not statistically significant. A
possible explanation for this apparent discrepancy is that six-
month follow-up depressive symptom severity was defined as a
dichotomous outcome in Yang and colleagues’ study, whereas it
was defined as a continuous outcome in the present study.
Supporting this interpretation, results of an exploratory analysis
we performed showed that baseline hs-CRP blood levels were
significantly higher among participants who were clinically
depressed at six-month follow-up (defined as a BDI-II score $
14), as compared with participants who were not (26.9641.1 mg/l
(n=4) vs 5.666.3 mg/l (n=21); mean difference, 21.3 mg/l; 95%
confidence interval, 3.3 to 39.3 mg/l; P= 0.022). The same
between-group comparison for interleukin-6 blood levels at
baseline approached statistical significance (16.0615.4 pg/ml
(n=4) vs 7.067.9 pg/ml (n=21); mean difference, 8.5 pg/ml;
95% confidence interval, 1.4 to 19.4 pg/ml; P = 0.09). In the
second study, Poole and colleagues found that elevated hs-CRP
levels at postoperative day four mediated the association between
depression and an increased length of stay [39]. Differences in the
aims and designs of this study compared with the present one limit
the ability to directly compare and contrast their findings.
The present study has limitations. First, some studies have
shown that cardiopulmonary bypass can produce a transient
elevation in blood S-100B levels, potentially confounding the
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observed correlation between perioperative increases in S-100B
levels and acute changes in depressive symptom severity [101].
However, subsequent studies, which performed serial assays of
blood S-100B levels among patients undergoing coronary artery
bypass grafting found that increases in blood S-100B levels due to
cardiopulmonary bypass are no longer apparent after 24 hours
[102,103]. Accordingly, because we collected postoperative blood
samples at about 48 hours, it is unlikely that perioperative
increases in S-100B levels in our study were related to
cardiopulmonary bypass. Supporting this interpretation, periop-
erative increases in S-100B levels among participants in our study
did not differ significantly between patients who had cardiopul-
monary bypass and those who did not. Second, whether the
observed perioperative increases in blood S-100B levels are
reliably attributable to glial activation and injury and blood-brain
barrier disruption rather than non-cardiac extracerebral sources
remains subject to interpretation. This concern arises primarily in
the context of two animal model studies having shown a
disconnect between S-100B levels in blood and those in CSF or
brain parenchyma [68], and one recent cross-sectional study that
found a negative correlation between CSF levels of S-100B and
depressive symptom severity among patients with non-inflamma-
tory neurological disorders [62]. Arguing in the opposite direction,
however, other studies have shown that extracerebral sources do
not influence blood S-100B levels [104]. In addition, a recent
study of patients undergoing coronary artery bypass grafting found
that S-100B levels in both blood and CSF increased together with
those of the quintessential astroglial marker glial fibrillary acidic
protein as well as CSF-to-serum albumin ratios [81]. Last, since
data on antidepressant and statin use were not collected for the
original Scarecrow trial, the effect of these drugs on the observed
correlation between changes in S-100B levels and acute changes in
depressive symptom severity cannot be excluded.
In conclusion, perioperative increases in S-100B levels exhibited
a strongly positive correlation with acute changes in depressive
symptom severity in the systemic inflammatory challenge para-
digm of cardiac surgery. There were no significant associations
between either acute or delayed changes in depressive symptom
severity and baseline S-100B levels, baseline hs-CRP or interleu-
kin-6 levels, or perioperative changes in hs-CRP or interleukin-6
levels. Among most participants, levels of all three biomarkers
were normal at baseline and markedly elevated at 2 days
postoperative. Taken together, these findings are consistent with
the hypothesis that depression can be mechanistically linked to
glial activation and injury as well as blood-brain barrier disruption
in the context of systemic inflammation challenge paradigms, to
include cardiac surgery. Large prospective cohort studies that can
inform the reproducibility of these findings are warranted.
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